Latest Data


« Topic Nektar Commences Phase 2 Clinical Development Program For Nktr-102 (peg-irinotecan) In Colorectal Cancer | Main | Subject Genetic Breast Cancer Test Approved (healthday) »

New Entry Molecular Insight Pharmaceuticals, Inc. Initiates Phase 2a Azedra(tm) Clinical Trial In Neuroblastoma Patients

By admin2 | May 25, 2008

MedicalMolecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that it has initiated a Phase 2a clinical trial of Azedra (Ultratraceā„¢ iobenguane I-131 or Ultratrace MIBG) for the treatment of children with high-risk neuroblastoma, a neuroendocrine cancer that primarily affects children. Azedra is already being evaluated in an ongoing dose-ranging clinical trial for pheochromocytoma in adults.
(Link)

This entry was important to me: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • StumbleUpon
  • Digg
  • del.icio.us
  • Reddit
  • Furl
  • Junipo

Topics: Cancer |

Comments